As of 2024-12-15, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -0.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 36.72 mil USD. OCX's TTM EBITDA according to its financial statements is -41.35 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (36.69) - (37.92) | (36.82) |
| Upside | -1681.6% - -1734.5% | -1686.9% |
| Date | EV/EBITDA |
| 2024-12-13 | -0.89 |
| 2024-12-12 | -0.92 |
| 2024-12-11 | -0.92 |
| 2024-12-10 | -0.96 |
| 2024-12-09 | -0.95 |
| 2024-12-06 | -0.94 |
| 2024-12-05 | -0.88 |
| 2024-12-04 | -0.92 |
| 2024-12-03 | -0.92 |
| 2024-12-02 | -0.94 |
| 2024-11-29 | -0.94 |
| 2024-11-27 | -0.93 |
| 2024-11-26 | -0.97 |
| 2024-11-25 | -1.02 |
| 2024-11-22 | -1.05 |
| 2024-11-21 | -1.03 |
| 2024-11-20 | -1.06 |
| 2024-11-19 | -0.98 |
| 2024-11-18 | -1.01 |
| 2024-11-15 | -1.01 |
| 2024-11-14 | -1.08 |
| 2024-11-13 | -1.14 |
| 2024-11-12 | -1.17 |
| 2024-11-11 | -1.12 |
| 2024-11-08 | -1.11 |
| 2024-11-07 | -1.10 |
| 2024-11-06 | -1.10 |
| 2024-11-05 | -1.13 |
| 2024-11-04 | -1.12 |
| 2024-11-01 | -1.17 |
| 2024-10-31 | -1.18 |
| 2024-10-30 | -1.17 |
| 2024-10-29 | -1.21 |
| 2024-10-28 | -1.21 |
| 2024-10-25 | -1.18 |
| 2024-10-24 | -1.19 |
| 2024-10-23 | -1.23 |
| 2024-10-22 | -1.20 |
| 2024-10-21 | -1.21 |
| 2024-10-18 | -1.22 |
| 2024-10-17 | -1.21 |
| 2024-10-16 | -1.21 |
| 2024-10-15 | -1.21 |
| 2024-10-14 | -1.21 |
| 2024-10-11 | -1.19 |
| 2024-10-10 | -1.21 |
| 2024-10-09 | -1.19 |
| 2024-10-08 | -1.18 |
| 2024-10-07 | -1.17 |
| 2024-10-04 | -1.12 |